NCT03304626View on ClinicalTrials.gov

Budesonide for Liver Transplant Immune Suppression

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 27, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Acute Cellular Graft RejectionNew Onset Diabetes After Transplant
Interventions
DRUG

Budesonide 3Mg Capsule

Budesonide capsule in place of prednisone (standard of care)

DRUG

Standard of Care Prednisone

Prednisone taper (Standard of Care)

Trial Locations (1)

45219

University of Cincinnati Medical Center, Cincinnati

All Listed Sponsors
collaborator

American College of Gastroenterology

OTHER

lead

University of Cincinnati

OTHER

NCT03304626 - Budesonide for Liver Transplant Immune Suppression | Biotech Hunter | Biotech Hunter